Center of excellence for bioavailability enhancement & drug delivery
Our team in Bend, Oregon (US) specializes, among other things, in addressing solubility challenges and modulating pharmacokinetics to meet target product profiles. The Bend site has specialized expertise, capabilities and infrastructure for spray-dried dispersion (SDD) technology which is increasingly being utilized for advancing poorly soluble molecules (BCS II compounds). A full range of oral drug delivery technologies and processing is also in place for modified and targeted release requirements in monolithic or multiparticulate formats.
The Bend site is staffed and equipped to support you throughout the entire lifecycle of your candidate, from preclinical and first in human to late-stage development and commercial production of drug product intermediates (SDD) and finished drug products.
Spray-dried dispersion technology
Spray-dried dispersion (SDD) technology was pioneered by Bend Research, now Lonza, and is now an intregral part of our integrated drug development services and network. SDDs are single-phase, amorphous molecular dispersions of a drug in a polymer matrix and are obtained by dissolving drug and polymer in an organic solvent and then spray-drying this solution. SDDs have a broad application space across BCS II molecules and demonstrate long-term stability, facile scale-up and excellent manufacturability. Hot melt extrusion (HME) technology is another solid amorphous dispersion option, with the choice between the technologies dependent upon API characteristics, target product profile and/or commercial objectives.
This expertise in particle engineering has been utilized in creating a full-service offering for dry powder inhaler (DPI) formulations. DPI formulations are designed to meet target product profiles using jet milling and/or spray drying. Our integrated services include phase-appropriate encapsulation and specialized analytical services.